ALDOA

Across TCGA pan-cancer cohorts, ALDOA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALDOA data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALDOA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALDOA expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

LUAD, GBM, and HNSC are the cancer types where ALDOA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.351	0.958	<.001	24	view →
GBM	DFS	Median	All	0.463	0.245	.005	7	view →
HNSC	OS	Tertile	All	1.000	0.770	.015	6	view →
LSCC	DFS	Tertile	All	0.765	0.492	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALDOA–LUAD (DFS)

Open the LUAD breakdown →